OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Drug Safety is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	60
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	50
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	32
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	31
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	21
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	21
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	20
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study	20
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	18
Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record	18
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	17
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	16
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	16
Corrigendum	15
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	15
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	14
Increasing patient involvement through self-administration of medication	13
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	13
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	11
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience	11
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	10
Impact of risk communication on patient’s safety during the pandemic	10
Data mining results for reduction of adverse drug–drug interaction events in older adults are clinically applicable	9
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States	9
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	8

Impact of social determinants of health on safety of patients in device clinical trials conducted at a safety-net hospital	8
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	8
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	8
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	7
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic	7
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	7
Artificial intelligence in drug development: reshaping the therapeutic landscape	7
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts	7
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	7
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	6
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries	6
Drug safety of frequently used drugs and substances for self-medication in COVID-19	6
The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System	6
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	6
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	6
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database	6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	6
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization	6
Is there a risk of esketamine misuse in clinical practice?	6
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries	6